Champions Oncology Announces Appointment of New CEO
Champions Oncology (NASDAQ:CSBR), a provider of oncology-focused CRO services, has appointed Rob Brainin as its new CEO and Board member, effective August 25, 2025. Brainin, who has served on Champions' Board since 2021, will succeed Dr. Ronnie Morris, who transitions to Executive Chair after serving as CEO since 2017.
Brainin brings over 25 years of life sciences and technology experience, most recently serving as Chief Business Officer at Veracyte. The leadership change comes as Champions aims to expand beyond core CRO services into data offerings, leveraging Brainin's expertise in scaling businesses built on science and data capabilities.
Current Chairman Joel Ackerman will transition to a Director role, while Dr. Morris will remain actively involved in strategic initiatives as Executive Chair.
Champions Oncology (NASDAQ:CSBR), fornitore di servizi CRO specializzati in oncologia, ha nominato Rob Brainin come nuovo CEO e membro del Consiglio di Amministrazione, a partire dal 25 agosto 2025. Brainin, che fa parte del Consiglio di Champions dal 2021, succede a Dr. Ronnie Morris, che passa al ruolo di Presidente Esecutivo dopo aver ricoperto la carica di CEO dal 2017.
Brainin porta con sé oltre 25 anni di esperienza nel settore delle scienze della vita e della tecnologia, avendo ricoperto recentemente il ruolo di Chief Business Officer presso Veracyte. Il cambio alla guida avviene mentre Champions punta a espandersi oltre i servizi CRO tradizionali, entrando nel campo delle offerte di dati, sfruttando l’esperienza di Brainin nella crescita di aziende basate su scienza e capacità analitiche.
L’attuale Presidente Joel Ackerman passerà a un ruolo di Direttore, mentre il Dr. Morris resterà attivamente coinvolto nelle iniziative strategiche come Presidente Esecutivo.
Champions Oncology (NASDAQ:CSBR), proveedor de servicios CRO enfocados en oncología, ha nombrado a Rob Brainin como su nuevo CEO y miembro de la Junta Directiva, con efecto a partir del 25 de agosto de 2025. Brainin, quien ha formado parte de la Junta de Champions desde 2021, sucederá a Dr. Ronnie Morris, quien pasará a ser Presidente Ejecutivo tras haber sido CEO desde 2017.
Brainin aporta más de 25 años de experiencia en ciencias de la vida y tecnología, habiendo sido recientemente Chief Business Officer en Veracyte. El cambio en el liderazgo se produce mientras Champions busca expandirse más allá de los servicios CRO básicos hacia ofertas de datos, aprovechando la experiencia de Brainin en escalar negocios basados en ciencia y capacidades de datos.
El actual presidente Joel Ackerman pasará a un rol de Director, mientras que el Dr. Morris permanecerá activamente involucrado en iniciativas estratégicas como Presidente Ejecutivo.
Champions Oncology (NASDAQ:CSBR)는 종양학에 특화된 CRO 서비스 제공업체로서, Rob Brainin을 2025년 8월 25일부로 새로운 CEO 겸 이사회 멤버로 임명했습니다. Brainin은 2021년부터 Champions 이사회에 참여해 왔으며, 2017년부터 CEO를 역임한 Dr. Ronnie Morris의 뒤를 이어 Executive Chair로 자리를 옮깁니다.
Brainin은 생명과학과 기술 분야에서 25년 이상의 경력을 보유하고 있으며, 최근에는 Veracyte에서 Chief Business Officer로 근무했습니다. 이번 리더십 교체는 Champions가 핵심 CRO 서비스를 넘어 데이터 제공 분야로 확장하려는 가운데, 과학과 데이터 역량을 기반으로 한 비즈니스 확장 경험을 가진 Brainin의 전문성을 활용하기 위한 것입니다.
현재 회장인 Joel Ackerman은 이사 역할로 전환하며, Morris 박사는 Executive Chair로서 전략적 이니셔티브에 계속 적극 참여할 예정입니다.
Champions Oncology (NASDAQ:CSBR), fournisseur de services CRO spécialisés en oncologie, a nommé Rob Brainin comme nouveau PDG et membre du conseil d'administration, à compter du 25 août 2025. Brainin, qui siège au conseil de Champions depuis 2021, succède à Dr. Ronnie Morris, qui devient Président exécutif après avoir été PDG depuis 2017.
Brainin apporte plus de 25 ans d'expérience dans les sciences de la vie et la technologie, ayant récemment occupé le poste de Chief Business Officer chez Veracyte. Ce changement de direction intervient alors que Champions cherche à s'étendre au-delà des services CRO traditionnels vers des offres de données, en s'appuyant sur l'expertise de Brainin dans le développement d'entreprises basées sur la science et les capacités de données.
Le président actuel, Joel Ackerman, passera à un rôle de directeur, tandis que le Dr Morris restera activement impliqué dans les initiatives stratégiques en tant que Président exécutif.
Champions Oncology (NASDAQ:CSBR), ein Anbieter von auf Onkologie spezialisierten CRO-Dienstleistungen, hat Rob Brainin als neuen CEO und Vorstandsmitglied mit Wirkung zum 25. August 2025 ernannt. Brainin, der seit 2021 im Vorstand von Champions tätig ist, wird Dr. Ronnie Morris nachfolgen, der nach seiner Tätigkeit als CEO seit 2017 zum Executive Chair wechselt.
Brainin bringt über 25 Jahre Erfahrung in den Bereichen Life Sciences und Technologie mit und war zuletzt Chief Business Officer bei Veracyte. Der Führungswechsel erfolgt, während Champions plant, über die Kern-CRO-Dienstleistungen hinaus in den Bereich Datenangebote zu expandieren und dabei Brainins Expertise in der Skalierung von wissenschafts- und datenbasierten Unternehmen zu nutzen.
Der bisherige Vorsitzende Joel Ackerman wird in eine Direktorenrolle wechseln, während Dr. Morris als Executive Chair weiterhin aktiv an strategischen Initiativen beteiligt bleibt.
- None.
- Potential disruption during leadership transition period
- Execution risk in planned expansion beyond core CRO services
HACKENSACK, NJ / ACCESS Newswire / July 18, 2025 / Champions Oncology (NASDAQ:CSBR), a leading provider of oncology-focused CRO services specializing in preclinical and clinical specialty testing, today announced that its Board of Directors has appointed Rob Brainin as Chief Executive Officer and member of the Board of Directors, effective August 25, 2025.
Rob, who has served on Champions' Board since 2021, will succeed Dr. Ronnie Morris, who has led the company as CEO since 2017. Dr. Morris will transition to the role of Executive Chair on August 25, supporting the leadership transition while remaining actively involved in the company's strategic initiatives.
"I want to thank Ronnie for his outstanding leadership and vision since 2017, and I am thrilled he will continue to play an integral role as Executive Chair," said Joel Ackerman, Chairman of the Board, who will transition to a Director role. "As we expand beyond our core CRO services into a robust data offering, Rob's expertise and track record of driving growth in innovative life sciences businesses make him the ideal leader to guide Champions through its next chapter."
Rob Brainin brings more than 25 years of experience in life sciences and technology, with a proven ability to scale and grow businesses built on cutting-edge science and data capabilities. He most recently served as Chief Business Officer at Veracyte, an oncology diagnostics company, and previously as CEO of Genuity Science, a company focused on genomics, data, and therapeutic discovery.
"I am honored and excited to join Champions at such a pivotal time," said Brainin. "The strength of Champions' core CRO services provides a tremendous foundation to expand our emerging data platform and advance the pipeline of our discovery therapeutics subsidiary, Corellia AI. I look forward to working alongside this talented team to build on the company's momentum and create value for our customers, employees, and shareholders."
Dr. Morris added, "I am incredibly proud of what we have accomplished together and the outstanding team we have assembled. I have complete confidence that Rob is the right leader to take Champions into its next phase of growth, and I look forward to supporting him and the team in realizing the company's full potential."
About Champions Oncology
Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.
Media Contact
Gavin Cooper
Vice President, Global Marketing
gcooper@championsoncology.com
518 488 9026
SOURCE: Champions Oncology, Inc.
View the original press release on ACCESS Newswire
FAQ
Who is the new CEO of Champions Oncology (NASDAQ:CSBR)?
Why is Champions Oncology (NASDAQ:CSBR) changing its CEO?
What happens to Champions Oncology's current CEO Dr. Ronnie Morris?
What is Rob Brainin's background before joining Champions Oncology as CEO?
What are Champions Oncology's expansion plans under the new CEO?
